Dosimetry Group for Gynecologic Cancers

"The eligibility requirements for this study allow people that are aged 18 or older and no more than 99 years old to participate."

"The listing on clinicaltrials.gov does show that this research is looking for participants right now. This specific trial was originally posted on August 10th, 2017 and updated most recently on May 11th, 2022. They need 52 individuals total, but only have 1 site at the moment."

"There are a total of 19 clinical trials currently underway that are focusing on this treatment. Of those, 0 are in Phase 3. Many of the studies related to this topic are based out of Baltimore, but there 28 research centres across the United States working on these investigations."

"This treatment can be effective for patients with increased prostate specific antigen levels, suspected metastasis, and positive results from positron emission tomography."

"At Power, we gave this treatment a safety rating of 2. This is because it is only in Phase 2 trials, meaning that while there has been some data supporting its safety, there is no evidence yet that the treatment is effective."

"This particular trial is testing a new intervention on 52 individuals that have gynecologic cancers. The ages of these patients range from 18 to 99 years old. There are a few requirements for participants which are as follows: being scheduled for or having already undergone a hysterectomy and/or salpingo-oophorectomy, being female, and being over the age of 18. Some participants may also have suspected gynecological cancer while others do not."

"That is accurate. The information available on clinicaltrials.gov affirms that the research team is still looking for patients to enrol in this clinical trial. This particular study was originally posted on 8/10/2017 and was last edited on 5/11/2022; it is hoping to have 52 people participate at 1 site."